New population-based data suggest that patients who don t receive care for NSTEMI within 24 hours have a substantially increased risk of mortality 3 years later.
Measurement of the biomarker copeptin in the ambulance may allow medics to quickly rule out myocardial infarction in patients with chest pain, randomized results of the AROMI trial suggest.
Target-lesion failures at 1 year were less common in diabetic patients treated with the polymer-free Cre8 EVO drug elution stent, compared to Resolute Onyx DES.
The clinical practice guideline offers a contemporary approach to determine which patients need further testing and which do not, and discourages the use of atypical in favor of noncardiac chest pain.